STEMCELL TECHNOLOGIES UK LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +1.1%

  £62,549,799 → £63,247,283

• Cash

  -2.3%

  £1,849,317 → £1,806,319

• Net assets

  +73.7%

  £4,587,994 → £7,970,622

• Employees

  +15.4%

  201 → 232

• Operating profit

  +114.5%

  £2,081,543 → £4,464,584

• Profit before tax

  +126.7%

  £1,893,266 → £4,292,423

• Wages

  +17.4%

  £12,784,416 → £15,012,362

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Oury Clark Chartered Accountants

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least 12 months and 1 day from when the financial statements are authorised for issue.”

Group structure

1. STEMCELL TECHNOLOGIES UK LTD · parent
   1. Stemcell Technologies GmbH 100% · Germany · Sales and marketing
   2. Stemcell Technologies SARL 100% · France · Sales and marketing
   3. Stemcell Technologies Netherlands B.V. 100% · Netherlands · Research and Development

Significant events

• “For the year ended 30 June 2024, turnover... did not meet expectations due to: Inflation which leads to high interest rates, preventing Biotech & Pharma companies from taking risks... A reduced equity financing capacity... From the middle of the financial year, the company tried to compensate for it, through temporary saving measures.”
• “STEMCELL has been a recipient of Canada's Best Managed Companies award since 2019.”
• “The 2024 Annual Employee Engagement Survey results showed an 81% engagement score, which is 8% above the global benchmark and 5% above the industry average.”
• “For the second consecutive year, STEMCELL was recognized as an I.D.E.A.L. Bioscience Employer.”
• “In November 2023, STEMCELL received Canada's Most Admired™™ Corporate Cultures award from Waterstone Human Capital.”
• “In 2024, we committed to the Science Based Targets initiative (SBTi)5 to align and validate our greenhouse gas (GHG) emissions reduction targets with the Paris Agreement goals.”
• “In 2023, STEMCELL became a signatory of the UN Global Compact.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

1

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.